Last updated: 2026-10-13 23:51:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
SCYNEXIS, Inc. (SCYX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.95, with a market capitalisation of $40.59M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.53 to $9.12. This page covers its latest market performance, valuation, price trends and company information.
$40.59M | |
$4.03 | |
$1,200.00 | |
$3.53 | |
$4.03 | |
65.72K | |
282.76K | |
-- | |
$9.12 | |
$3.53 | |
-- | |
-- |
SCYNEXIS, Inc. (SCYX) is trading at $3.95 in after-hours trading as of 2026-10-13 23:47:00, down 2.11% ($0.09) from the regular-session close of $4.03.
After-hours trading shows how investors are pricing SCYX after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, SCYNEXIS, Inc. (SCYX) moved from $5.12 to $3.95, representing a decline of 22.95% ($1.18).
The stock traded between $3.93 and $5.51 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 180.86 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 7.4%
SCYX is currently trading at $3.95, placing it 7.4% of the way from its 52-week low of $3.53 to its 52-week high of $9.12. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SCYNEXIS, Inc. (SCYX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.